DXC006

Phase 1Small molecule

HHangzhou DAC Biotechnology Co., Ltd.

DXC006 is one of 40 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Solid Tumor

NCT06224855

Q4 2030

PreclinicalRecruiting

Small Cell Lung Cancer

NCT07559929

Clinical

Trials by Indication[1]

Solid Tumor1 trial

An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Recruiting·HHangzhou DAC Biotechnology Co., Ltd.·Phase 1·NCT06224855·280 enrolled

Small Cell Lung Cancer1 trial

A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.

Recruiting·HHangzhou DAC Biotechnology Co., Ltd.·Preclinical·NCT07559929·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DXC006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DXC006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DXC006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou DAC Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHangzhou DAC Biotechnology Co., Ltd.

DXC006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Solid Tumor1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News